Murine double minute clone 2 (MDM2) is a multifunctional protein, which modulates nuclear receptor-mediated transactivation. In this study, we show that MDM2 significantly enhanced estrogen receptor a (ERa) and ERa/specificity protein-mediated transactivation in MCF-7 and ZR-75 breast cancer cells. This was demonstrated by both MDM2 overexpression and knockdown experiments by RNA interference. ERa interacted with wild-type MDM2 and deletion mutants of MDM2 containing amino acids 1-342 (C-terminal deletion) and 134-490 (N-terminal deletion), but not 134-342. In contrast, only wild-type but not mutant MDM2 enhanced ERa-mediated transactivation. Protein-protein interactions in vitro were 17b-estradiol (E 2 ) independent, whereas fluorescent resonance energy transfer experiments in living cells showed that E 2 enhanced ERa-MDM2 interactions. Subsequent RNA interference and mammalian twohybrid experiments suggested that MDM2 did not directly interact with endogenous coactivators such as the steroid receptor coactivators but played a role in enhancing ERa-mediating gene expression and estrogen responsiveness through interactions with ERa.
Introduction
Murine double minute clone 2 (MDM2) was initially cloned from a transformed 3T3 cell line, and later identified as a p53-interacting protein (Cahilly-Snyder et al. 1987 , Fakharzadeh et al. 1991 , Momand et al. 1992 . It was subsequently shown that overexpression of MDM2 resulted in cell transformation and oncogenicity and this was due, in part, to suppression of the tumor suppressor gene p53. The complex interrelationships between MDM2 and p53 have been extensively investigated (Levav-Cohen et al. 2005 , Brooks & Gu 2006 . MDM2 exhibits E3-ubiquitin ligase activity, which increases ubiquitination of p53 and, in combination with other factors, the resulting proteasome-dependent degradation of p53 decreases expression of this tumor suppressor gene under nonstressed conditions (Ashcroft et al. 1999 . The role of MDM2 in regulating p53 expression is also apparent in transgenic mice where MDM2 knockout animals exhibit embryolethality, which is reversed by inactivation of p53 (Jones et al. 1995 , Montes de Oca Luna et al. 1995 , de Rozieres et al. 2000 . Under conditions of cellular stress, the physical and functional interactions of MDM2 and p53 are inhibited, thereby allowing p53 to activate gene expression pathways, such as inhibition of cell cycle progress and induction of apoptosis, which allow the cells to respond to stressors. The interactions between p53 and MDM2 are complex and are modified under various conditions and in a cell/tissue context-dependent manner (Brooks & Gu 2006) .
Since MDM2 inhibits p53 function as a tumor suppressor gene, it is not surprising that expression of MDM2 plays a role in cancer and in cancer prognosis (Levav-Cohen et al. 2005) . Overexpression of MDM2 is frequently observed in many different cancers; however, the prognosis for patients in which MDM2 levels are high is dependent on multiple factors including the type of tumor and its origin. For example, MDM2 overexpression through gene amplification in gliomas predicts poor survival (Korkolopoulou et al. 1997 , Rainov et al. 1997 , Schiebe et al. 2000 , whereas overexpression through gene amplification in breast cancer is observed only in estrogen receptor (ER)-positive tumors for which there is a good prognosis for survival (Bueso-Ramos et al. 1996 , Lukas et al. 2001 , Hori et al. 2002 . The variability of MDM2 as a prognostic indicator for cancer survival is complex and may be due to interactions with other unknown factors.
A number of p53-independent functions of MDM2 have been identified and show that this protein can modify different signaling pathways. MDM2 interacts with and inhibits the function of retinoblastoma (Rb) protein and other Rb family members (Hsieh et al. 1999) and this affects E2F1-DP1-mediated responses (Martin et al. 1995) and also enhances the transcriptional activation of cyclin A (Leveillard & Wasylyk 1997) . MDM2 also modulates ligand-dependent activation of several steroid hormone receptors including the glucocorticoid receptor, androgen receptor, and ER (Liu et al. 2000 , Saji et al. 2001 , Sengupta & Wasylyk 2004 . MDM2 overexpression in MCF-7 human breast cancer cells enhances their estrogen-dependent growth and, in p53-deficient Saos-2 osteosarcoma cells and MCF-7 cells, MDM2 enhances 17b-estradiol (E 2 )-dependent activation of a construct containing an estrogen response element (ERE) insert (Saji et al. 2001) .
This study shows by RNA interference that MDM2 enhances E 2 -dependent growth and transactivation in breast cancer cells using constructs containing three tandem EREs or GC-rich motifs (pSP1 3 ) activated by ERa or ERa/SP1 respectively. MDM2 overexpression also coactivates ERa and ERa/SP1, and the results suggest that the coactivation response is primarily through direct interactions of MDM2 with ERa and MDM2-dependent enhanced interactions of ERa with coactivators.
Materials and methods

Cell lines, chemicals, and biochemicals
The ZR-75 (ZR-75.1), MCF-7, and T47D human breast cancer cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were cultured in RPMI 1640 or DMEM (Sigma) supplemented with 5 or 10% FBS and the medium was further supplemented with antibiotic/antimycotic solution (Sigma). Prior to transfection, RPMI or DMEM medium was replaced by DMEM/F-12 (Sigma) supplemented with charcoal-stripped 10% FBS. Cells were maintained at 37 8C with a humidified CO 2 /air (5:95) mixture. Small inhibitory RNA (siRNA) duplexes for MDM2 (siMDM2), p53 (sip53), luciferase (siGL2), and the scrambled siRNA (siCT) were purchased either from Ambion (Austin, TX, USA) or Sigma-Aldrich. The sequence for siGL2: 5 0 -CGU ACG CGG AAU ACU UCG ATT-3 0 ; for siMDM2: 5 0 -GAA CAA GAG ACC CTG GTT A-3 0 ; for sip53: 5 0 -GAG GUU GGC UCU GAC UGU A-3 0 ; for scrambled RNA (siCT): 5 0 -ACU CUA UCU GCA CGC UGA CTT-3 0 .
Plasmids and cloning pERE 3 , pSP1 3 , pCAD, and pE2F1 were previously generated in our laboratory. pcDNA-MDM2 (490 aa) was kindly provided by Dr Lane (University of Dundee, UK). The MDM2 deletion mutants (135-490 aa, 135-342 aa, and 1-342 aa) were generated by cloning MDM2 deletion mutant amplified PCR products into EcoRI/ XhoI sites of pcDNA3.1His plasmid. MDM2 deletion mutants were generated by PCR using following primer sets: 1-342 aa: (F) 5 0 -GAA TTC ATG TGC AAT ACC AAC  ATG TC-3 0 , (R) 5 0 -CTC GAG TTT TTC AGA GAT TTC  CAC-3 0 ; 134-490 aa: (F) 5 0 -GAA TTC CCT TTG CAA GCG CCA CCA G-3 0 , (R) 5 0 -CTC GAG CTA GTT GAA GTA AGT TAG CAC-3 0 ; 135-342 aa: (F) 5 0 -GAA TTC CCT TTG CAA GCG CCA CCA G-3 0 , (R) 5 0 -CTC GAG TTT TTC AGA GAT TTC CAC-3 0 . These generated Xpress-tagged expression plasmids were also used for in vitro coimmunoprecipitation assays. pMMDM2 and VP-MDM2 expression plasmids were generated by PCR amplification of MDM2 wild-type and cloned into EcoRI and HindIII sites of pM and VP16 vectors (Clontech). For ECFP-MDM2 vector generation, the amplified MDM2 PCR product was digested with EcoRI and XhoI, and cloned into CFP-C1 vector (Clontech). The GAL4-coactivator fusion plasmids pMSRC-1, pMGRIPwt, and pMAIB-1 were kindly provided by Dr Shigeaki Kato (University of Tokyo, Tokyo, Japan), and pMGRIP(LXXLL) (fused to the yeast GAL4 DBD) was obtained from Dr Donald McDonnell (Duke University, Durham, NC, USA).
Transient transfection assays
The cells were seeded into 12-well plates in phenol-free DMEM/F-12 supplemented with 5% charcoal-stripped FBS. After 24 h, cells were transfected by lipofectamine 2000 reagent (Invitrogen) with 250 ng of an appropriate reporter plasmid (pERE 3 , pSP1 3 , pCAD, pE2F1, or GAL4-luciferase), 50 ng of a CMV b-galactosidase expression plasmid, and other appropriate expression plasmids (125 ng/well) (ERa, MDM2 wild-type and mutants (1-342 aa, 134-490 aa, and 134-490 aa)), pMERa, pMMDM2, VP-ERa, or VP-MDM2. Empty vectors or nonspecific (siCT) oligonucleotides were used as controls in all transfection experiments. After transfection for 24 h, cells were treated with Me 2 SO or 10 nmol/l E 2 with 5% stripped serum media for 24 h. In cells transfected with siRNA(s), E 2 was added after 36-48 h for accomplishing efficient knockdown of target gene. Cells were then harvested, and luciferase activity (relative to b-galactosidase activity) was determined. Normalized luciferase values were obtained by dividing the luciferase by the b-galactosidase activities for a given sample. The results are expressed as meansGS.E.M. for at least three separate experiments for each treatment group.
In vitro coimmunoprecipitation assay S-labeled MDM2 wild-type or deletion mutant protein (0 . 5 ml) were coincubated in coimmunoprecipitation buffer (sterilized PBS C0 . 01% IGEPAL CA630) with E 2 to give a final concentration of 100 nM E 2 . After incubation for 1 h at 4 8C, 25 ml of 50% slurry of protein G-sepharose beads (Amersham Biosciences) were added to the incubation solution, followed by incubation for 2 h on a rocker at 4 8C. Samples were then centrifuged and washed, the final pellet was boiled in 30 ml of 2! SDS sample buffer, and proteins were separated on a 8% SDS-PAGE and visualized by autoradiography.
Western blot analysis
Depletion of MDM2 protein was determined, 48 h after transfection with siRNA for MDM2, breast cancer cells were harvested with RIPA lysis buffer (1! PBS, 1% Nonidet P-40 or Igepal CA-630, 0 . 5% sodium deoxycholate, 0 . 1% SDS, 1 mg/ml phenylmethylsulfonyl fluoride in isopropanol, aprotinin, and 100 nM sodium orthovanadate), and equal amounts of protein from each group were boiled with sample buffer and loaded onto 8% SDS-polyacrylamide gel. The membrane was blocked and probed with primary antibodies for MDM2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) O/N at 4 8C. Membrane was visualized using the ECL detection system (PerkinElmer Life Sciences, Boston, MA, USA).
Cell proliferation assay
MCF-7 or ZR-75 cells (5!10 4 per well) were plated into 12-well plates and allowed to attach for 24 h, and then cells were transfected with either control siRNA or MDM2 siRNA. After 24 h, the medium was changed to charcoal-stripped 5% FBS DMEM medium containing either vehicle (DMSO) or estrogen (10 nM). Fresh medium was added every 48 h. Cells were then trypsinized and counted at the indicated times using a Coulter Z1 particle counter. Each experiment was performed in triplicate and the results are expressed as meansGS.E.M. for each treatment group.
Quantitative RT-PCR RNA was harvested from T47D cells using the RNeasy mini or micro kits (Qiagen). First-strand cDNA synthesis was performed with 1 mg RNA using Reverse Transcription kit from Promega. Real-time PCR was performed using SYBR Green PCR Master Mix reagent, the ABI PRISM 7000 sequence detection system, and software (Applied Biosystems, Foster City, CA, USA). 
Fluorescence resonance energy transfer analysis
The cells were grown in two-well Lab-Tek Chambered Coverglass slides (Nalge Nunc International, Rochester, NY, USA) in DME/F12 medium supplemented with 5% charcoal-stripped serum and then transfected with CFP-MDM2/YFP-ERa or CFP-SP1/YFP-ERa sets. All the procedures for measuring fluorescence resonance energy transfer (FRET) efficiency were previously described . Briefly, after transfection for 24 h, cells were put on the stage of a Bio-Rad 2000 MP microscope system (Bio-Rad Laboratories) equipped with a Nikon T#300 inverted microscope. The images were acquired between 5 and 15 min before and after the addition of 10 nM E 2 . FRET efficiency data were collected using two photon 820 nm excitation wavelength. Emission of CFP (CFP channel, donor signal) was collected using a 500DCLP dichroic and 450/80 nm filter, whereas emission of YFP (FRET channel, acceptor signal) was collected using a 528/50 nm filter. CFP-SP1/YFP-ERa set was used as positive control after E 2 treatment in this experiment. For FRET analysis, MetaMorph software version 6.0 (Universal Imaging Corp., Downingtown, PA, USA) was used and FRET signals were corrected by subtracting the background signal as well as the donor bleed through signal. At least 50 cells per treatment were analyzed by one-way ANOVA followed by Dunnett's test.
with ERa and MDM2 expression plasmids and an ERE reporter construct (Saji et al. 2001) . In this study, we first examined the effects of endogenous MDM2 on E 2 -induced transactivation in ZR-75 breast cancer cells transfected with pERE 3 (Fig. 1A Figure 1C and D show that MDM2 knockdown (siMDM2) inhibited E 2 -induced transactivation in ZR-75 cells transfected with the pERE 3 or pSP1 3 constructs; similar results were observed in ZR-75 cells transfected with E 2 -responsive GC-rich constructs containing promoter inserts from the E2F1 and CAD genes (Wang et al. 1999 , Khan et al. 2003 , Ngwenya & Safe 2003 ; data not shown). Moreover, in a mammalian two-hybrid assay in ZR-75 cells, we did not observe SP1-MDM2 interactions (data not shown). Results in Fig. 1E show that siMDM2 decreased siMDM2 protein expression in MCF-7 cells, increased p53 protein expression, and did not affect the levels of SP1 protein.
The effects of overexpression of MDM2 on coactivation of ERa and ERa/SP were investigated in MCF-7 cells transfected with pERE 3 ( Fig. 2A ) or pSP1 3 (Fig. 2B) , and the results showed that MDM2 significantly enhanced ERa and ERa/SP-mediated transactivation and similar results were observed in ZR-75 cells (data not shown). Coactivation of ERa by MDM2 was further investigated in MCF-7 ( Fig. 2C ) and ZR-75 ( Fig. 2D ) cells transfected with MDM2, a GAL4-ERa chimeric protein (pMER), and a construct (GAL4-luc) containing five tandem GAL4 response elements. The results show that E 2 significantly induced transactivation in both cell lines and this response was further enhanced by MDM2 expression. Moreover, E 2 -induced transactivation in MCF-7 cells transfected with pMER and GAL4-luc was significantly decreased after cotransfection with siMDM2 or siGL2 that knocks down luciferase ( Fig. 2E ), confirming that MDM2 coactivates ERa-mediated transactivation.
MDM2 interacts with ERa
It was previously reported that in a mammalian twohybrid assay in Saos-2 cells using pM-ERa and VP-MDM2, E 2 induced transactivation (interaction); however, in GST pull-down studies ERa interacted with MDM2 in the presence or absence of ligand (Saji et al. 2001) . Results in Fig. 3A show that in mammalian twohybrid assays in ZR-75 cells, there was increased transactivation in cells transfected with pM-MDM2 and VP-ERa compared with cells transfected with pM-MDM2 and VP and this interaction did not require the addition of E 2 . Moreover, in coimmunoprecipitation experiments with in vitro expressed 35 S-labeled ERa and MDM2 (Xpress-tagged), both proteins interacted in the presence or absence of E 2 (Fig. 3B) . The interactions of ERa and MDM2 in living cells were also investigated by FRET in cells transfected with a Figure 1 MDM2 knockdown inhibits estrogen-induced ERa and ERa/SP-mediated transactivation. MCF-7 cells were transfected with pERE 3 (A) or pSP1 3 (B) and ZR-75 cells were transfected with pERE 3 (C) or pSP1 3 (D) and various (or no) oligonucleotides and treated with DMSO or 10 nM E 2 . Luciferase activity was determined as described in the section 'Materials and methods'.
Significant (P!0 . 05) induction by E 2 (*) and inhibition by iMDM2 or iGL2 (**) are indicated. Results are expressed as means GS.E.M. for at least three separate determinations for each treatment group. Minimal activity was observed in cells transfected with the empty vector, and treatment with DMSO or E 2 did not induce activity. (E) MDM2 knockdown. MCF-7 cells were transfected with a nonspecific (siCT) or siMDM2 oligonucleotide, and whole cell lysates were analyzed by western blots as described in the section 'Materials and methods'. MCF-7 cells were used for whole cell lysate analysis due to higher transfection efficiency compared to ZR-75 cells.
CFP-MDM2 construct and a YFP-ERa construct. In preliminary experiments, we showed that similar to MDM2, ECFP-MDM2 also enhanced E 2 -dependent transactivation in ZR-75 cells transfected with pM-ERa/GAL4-luc (Fig. 3C) . FRET analysis was determined in MCF-7 cells transfected with CFP-MDM2 and YFP-ERa (Fig. 3D) . The FRET efficiencies obtained are illustrated in Fig. 3E and show that E 2 significantly enhanced this response, indicating that although both proteins directly interact in the absence of E 2 , treatment with hormone clearly enhances this interaction and facilitates the energy transfer between the CFP and YFP moieties in both proteins. As a positive control for this experiment, we also show that E 2 enhances YFP-ERa interactions with CFP-SP1 as previously reported . There was clearly a parallel between the significant effects of E 2 on FRET efficiencies associated with YFP-ERa-CFP-SP1 and YFPERa-CFP-MDM2 and the E 2 -independent interaction of ERa with both SP1 and MDM2 ( Fig. 3A and B) in coimmunoprecipitation experiments.
MDM2 contains several domains that interact with other proteins and also a zinc finger and a C-terminal RING finger domain that functions as an E3-ubiquitin ligase (Ashcroft et al. 1999 . We initially examined the interactions of wild-type and deletion variants of MDM2 (Xpress-tagged) with ERa, and . Lanes 1-6 illustrate the 35 S-labeled proteins alone. Thus, ERa interacts with both C-and N-terminal domains of MDM2 but not with the 134-342 aa region, which binds CBP/p300 (Grossman et al. 1998 ). In contrast, coactivation studies in ZR-75 cells transfected with pM-ERa showed that only wild-type, but not the deletion variants of MDM2, coactivated ERa (Fig. 4B) . These results suggest that multiple regions of MDM2 are required for coactivation of ERa.
MDM2 enhances interactions of ERa with steroid receptor coactivators
Steroid receptor coactivators (SRCs), mediator proteins, and p300 associate with ER as complexes that interact cyclically with E 2 -responsive gene promoters, and MDM2 has been identified as a component of these complexes . The role of MDM2 and its interactions with coactivators has been further investigated in mammalian two-hybrid assays using coactivator-GAL4 chimeras (pM-coactivators), VP-ERa, and GAL4-luc in ZR-75 cells. In cells transfected with pMGRIPwt, VP-ERa and GAL4-luc treatment with E 2 induced transactivation; however, E 2 -dependent interactions were significantly inhibited in cells cotransfected with siMDM2, suggesting that interactions of GRIP (SRC-2) and ERa are mediated, in part, by MDM2 (Fig. 5A) . Interactions of GRIP and MDM2 were also investigated in a mammalian two-hybrid assay in ZR-75 cells transfected with pMGRIP/GAL4-luc and VP-MDM2, and the results show that MDM2 and GRIP do not interact in the presence or absence of E 2 (Fig. 5B) . However, after cotransfection with ERa, there was a significant increase in transactivation, which was observed in the absence or presence of E 2 but was more pronounced in the former case. These results suggest that, although GRIP and MDM2 do not exhibit binding in a two-hybrid assay, the expression of ERa significantly enhanced interactions between GRIP and MDM2. ER-coactivator interactions are dependent, in part, on interactions between for at least three replicate determinations for each treatment group, and significant (P!0 . 05) induction is indicated (*). Full colour version of this figure available via http://dx.doi.org/10. 1677/JME-10-0110.
K KIM and others . MDM2 enhances estrogen responsiveness NR-box (LXXLL) motifs in coactivators (Torchia et al. 1997 , Voegel et al. 1998 with ERa, and Fig. 5C shows that E 2 induces transactivation in ZR-75 cells transfected with VP-ERa and pMGRIP(LXXLL)/GAL4-luc where pMGRIP(LXXLL) is a chimera containing GAL4 fused to aa629-760 from GRIP/SRC-2, which contains an LXXLL motif. E 2 -dependent interactions of ERa and GRIP(LXXLL) in the mammalian two-hybrid assay were inhibited after cotransfection with siMDM2, suggesting that MDM2 facilitates ERa interactions with the NR-box motif of GRIP. pMGRIP(LXXLL) did not interact with VP-MDM2 in a two-hybrid assay; however, cotransfection with ERa in the presence or absence of E 2 enhanced transactivation (Fig. 5D ).
These results suggest that ERa enhances MDM2 interactions with the NR-box motif of GRIP.
The role of MDM2 in the interaction of ERa with SRC-1 and SRC-3 (AIB-1) was also investigated in mammalian two-hybrid assays in ZR-75 cells (Fig. 6) , and the results were similar to those observed for ERa and GRIP. E 2 induced transactivation in cells transfected with pMSRC-1/GAL4-luc plus VP-ERa (Fig. 6A) or pMAIB-1/ GAL4-luc plus VP-ERa (Fig. 6B) . Cotransfection with siMDM2 inhibited basal and induced activity, and the inhibition was most pronounced for AIB-1-ER interactions. Interactions of pMSRC-1 and VP-MDM2 (Fig. 6C) or pMAIB-1 and VP-MDM2 (Fig. 6D) were not observed in mammalian two-hybrid assays; however, cotransfection with ERa significantly enhanced transactivation in the absence or presence of E 2 . The hormoneinduced response was more pronounced with pMAIB-1 compared to pMSRC-1; moreover, E 2 decreased transactivation in ZR-75 cells transfected with pMSRC-1, VP16-MDM2 and ERa, suggesting that liganded ERa may inhibit SRC-1-MDM2 interactions. These results demonstrate that although MDM2 does not interact with SRCs, this protein plays a key role in enhancing ERa interactions with the SRC coactivators. Results in Fig. 6E demonstrate that E 2 also induces transactivation in ZR-75 cells transfected pMp300/GAL4-luc and VP-ER; however, siMDM2 slightly enhances both basal and E 2 -induced activity. These results demonstrate the specificity of the SRC-ERa-MDM2 compared to that observed for p300-ERa-MDM2 interactions where MDM2 plays a key role in coactivator ERa interactions but not p300-ERa interactions. The 'constitutive' inhibitory effect may be due to the competitive binding of both ERa and MDM2 to p300 (Hanstein et al. 1996 , Grossman et al. 1998 ).
MDM2 enhances E 2 -dependent activation of pS2 and E2F1 and cell proliferation
The functional effects of MDM2 on hormone-induced gene expression were investigated in p53-expressing ZR-75 cells and T47D cells that do not express functional p53. In ZR-75 (Fig. 7A) and T47D (Fig. 7B ) cells transfected with siMDM2, induction of E2F1 protein expression was decreased after the loss of MDM2. The role of MDM2 in hormone-induced expression of E2F1 and pS2 mRNA levels in ZR-75 (Fig. 7C) and T47D (Fig. 7D ) cells was also determined, and the hormoneinduced responses were significantly decreased in cells transfected with siMDM2. Moreover, using a similar approach, knockdown of MDM2 by RNA interference in T47D cells decreased induction of CAD and cyclin D1 by E 2 (data not shown). Since p53 inhibits estrogen responsiveness, it is possible that the loss of hormoneinduced transactivation in breast cancer cells transfected with siMDM2 may be due, in part, to activation of MDM2 enhances estrogen responsiveness . K KIM and others 73 p53. We also compared the effects of hormone-induced transactivation in MCF-7 cells transfected with sip53, siMDM2, and their combination. E 2 induced pS2 and E2F1 gene expression in MCF-7 cells treated with E 2 and this response was decreased after cotransfection with siMDM2 or siMDM2 plus sip53, but unaffected by sip53 alone (data not shown). Similar results were observed for induction of luciferase activity in cells transfected with pSP1 3 and pERE 3 (data not shown), demonstrating that the effects of siMDM2 were p53 independent. Nutlin-3 is an MDM2 antagonist, which dissociates the MDM2-p53 complex, resulting in activation of p53 (Vassilev et al. 2004) . In T47D cells that do not express wild-type p53, addition of Nutlin-3 did not affect induction of E2F1 by E 2 (Fig. 7E) . In contrast, Nutlin-3 significantly decreased basal and E 2 -inducible E2F1 in ZR-75 cells that express wild-type p53 (Fig. 7D) , demonstrating that inhibition of MDM2, like knockdown of MDM2 (Figs 1 and 2) , decreased hormonal activation of E2F1. The effects of MDM2 knockdown on basal and E 2 -induced proliferation were also investigated in MCF-7 and ZR-75 cells (Fig. 7F) . The results show that loss of MDM2 in these cells decreased both basal and hormone-induced cell growth after 96 h, further demonstrating the critical role for MDM2 in both cell lines. These results confirm the important role of MDM2 as a coregulator of hormone-induced gene expression in breast cancer cells.
Discussion
Coactivators and other coregulatory proteins play a critical role in hormone receptor-dependent gene expression, and these nuclear proteins are essential factors for ligand-induced transcriptional activation (Blanco et al. 1998 , O'Malley 2007 . Initial studies describing coactivation of nuclear receptors by SRCs demonstrated several essential features of coactivator function. These included identification of NR-boxes required for specific coactivator-receptor interactions (Torchia et al. 1997 , Voegel et al. 1998 , histone acetyltransferase activity of some SRCs, which facilitates interaction of receptor-coregulatory complexes with promoter DNA, and interactions of coactivators with multiple domains of nuclear receptors and with other nuclear cofactors (Blanco et al. 1998 , O'Malley 2007 . This complexity associated with SRCs has been further magnified by ongoing studies that have identified many other classes of coactivators, which manifest their activities through ATP-dependent chromatin modeling, histone methylation, or modification of receptors through ubiquitination or sumoylation (Blanco et al. 1998 , O'Malley 2007 , O'Malley & Kumar 2009 . The interactions of different functional classes of nuclear factors in ERa-mediated transcriptional activation have been extensively investigated in chromatin immunoprecipitation (ChIP) assays, which demonstrate an ordered cycling of distinct cofactor/ERa complexes on and off the E 2 -responsive pS2 gene promoter (Shang et al. 2000 , Burakov et al. 2002 . MDM2, which exhibits E3-ubiquitin ligase activity, is involved in this cycling process, and previous studies have shown that MDM2 overexpression coactivates ERa-dependent transactivation in cells transfected with ERE-promoter constructs (Saji et al. 2001) . Research in this laboratory and others have demonstrated that E 2 also activates genes in breast cancer cells through ERa/SP interactions with GC-rich promoters (O'Malley 2007), and we have been investigating the coactivation of ERa and ERa/SP in breast cancer cells transfected with pERE 3 and pSP1 3 respectively (Kim et al. 2003 , Wu et al. 2004 , Lee et al. 2005 , Lee & Safe 2007 . Vitamin D interacting protein 150 (DRIP150) is a mediator complex protein (Koh et al. 2002 , Kouzmenko et al. 2004 , which coactivates ERa and ERa/SP1, and this 
DMSO E 2 * Figure 5 The effects of MDM2 on coactivation of ERa by GRIP (SRC-2). ZR-75 cells were treated with DMSO or 10 nM E 2 , and transfected with pMGRIPwt/VP-ERa and iCT or iMDM2 oligonucleotides (A) or pMGRIPwt/VP16-MDM2, empty vectors and hERa (B), and luciferase activity was determined as described in the section 'Materials and methods'. ZR-75 cells were treated with DMSO or 10 nM E 2 , transfected with pMGRIP(LXXLL)/VP-ERa and iCT or iMDM2 oligonucleotides (C) or pMGRIP(LXXLL) /VP16-MDM2, empty vectors and ERa (D), and luciferase activity was determined as described in the section 'Materials and methods'. The results are expressed as meansGS.E.M. for at least three replicate determinations for each treatment group, and significantly (P!0 . 05) enhanced interactions by ERa (*) and decreased activity by iMDM2 (**) are indicated.
K KIM and others . MDM2 enhances estrogen responsiveness involves an a-helical NIFSEVRVYN (amino acids 795-804) motif within a 23 amino acid sequence (789-811) in the central region of DRIP150 that does not contain an LXXLL box (Lee et al. 2005 , Lee & Safe 2007 . DRIP150 had minimal effects on SP-dependent transactivation and coactivated ERa and ERa/SP1 primarily through interactions with ERa (Lee & Safe 2007) . In this study, we demonstrate that E 2 -induced transactivation in breast cancer cells transfected with pSP1 3 or pERE 3 was significantly inhibited by knockdown of MDM2 by RNA interference (siMDM2) (Fig. 1A and B) , and overexpression of MdM2 also enhanced transactivation in cells transfected with pSP1 3 or pERE 3 constructs ( Fig. 2A and B) . We also observed that in ZR-75 and T47D cells transfected with siMDM2, there was a significant decrease in hormone-induced protein and mRNA levels (Fig. 7) , demonstrating a role for MDM2 in E 2 -induced gene expression. These results confirm coactivation of ERa by MDM2 as previously reported (Saji et al. 2001) and also show that MDM2 coactivates ERa/SP1. MDM2 did not interact with SP1 and knockdown or overexpression of MDM2 did not affect SP-dependent transactivation (Figs 1A and B and 2A and C) , suggesting that coactivation of ERa and ERa/SP is primarily associated with direct interactions between MDM2 and ERa.
MDM2 interacts with ERa in the presence or absence of E 2 (Fig. 3A and B ) and E 2 also enhances ERa-MDM2 interactions in living cells as determined by FRET analysis ( Fig. 3D and E) . It is clear from ChIP assays that ERa, MDM2, and other nuclear coregulatory proteins cycle on and off E 2 -responsive gene promoters in breast cancer cells, and there is also evidence that specific subsets of coactivators may be selectively recruited to the pS2 promoter . Since constitutively expressed and transiently overexpressed MDM2 activated ERa and ERa/SP1, it is possible that this protein may also act in concert with other nuclear cofactors such as the SRCs. Previous studies have demonstrated coactivation of ERa by SRCs (Blanco et al. 1998 , Vassilev et al. 2004 , O'Malley 2007 and corecruitment of MDM2 and SRCs to E 2 -responsive gene promoters and, therefore, we hypothesized that MDM2 acts, in part, through facilitating SRC-ERa interactions. Results in Figs 5 and 6 demonstrate that interactions of pMSRCs with VP-ERa are E 2 dependent, and similar results were observed with interactions of VP-ER with the GRIP1 LXXLL box (GAL4-GRIP(LXXLL)) (Fig. 5C ). These hormone-dependent ER-SRC interactions were not surprising; however, using RNA interference with siMDM2, it was evident that MDM2 facilitated ERa-SRC (Figs 5A and 6A, and C) but not ERa-p300 (Fig. 6E) interactions in a mammalian two-hybrid assay. Moreover, it was also apparent in mammalian two-hybrid assays in which cells were transfected with pMSRC and VP16-MDM2 that MDM2 did not directly interact with coactivators unless ERa was also overexpressed, and this resulted in increased transactivation in the presence or absence of E 2 (Figs 5B and 6B and D) .
These results suggest a model for MDM2 coactivation of ERa or ERa/SP1 in which MDM2 acts alone or in combination with SRCs to enhance transactivation. This resembles, in part, a similar model proposed for b-catenin, which enhances nuclear receptor or transcription factor-mediated transactivation alone and in combination with other coactivators (Koh et al. 2002 , Kouzmenko et al. 2004 , Li et al. 2004 . Figure 6 Effects of MDM2 on coactivation of ERa by other coactivators and p300. ZR-75 cells were treated with DMSO or 10 nM E 2 , transfected with pMSRC-1/VP-ERa (A) or pMAIB-1/ VP-ERa (B), GAL4-luc and siCT or siMDM2 oligonucleotides, and luciferase activity was determined as outlined in the section 'Materials and methods'. The effects of ERa on MDM2 coactivator interactions. ZR-75 cells were treated with DMSO or 10 nM E 2 , transfected with pMSRC-1/VP-MDM2 or pMAIB-1/VP-MDM2, empty vectors or ERa and GAL4-luc, and luciferase activity was determined as described in the section 'Materials and methods'. (E) The effect of MDM2 knockdown on ERa-p300 interactions. ZR-75 cells were treated with DMSO or 10 nM E 2 , transfected with pMp300/VP-ERa and GAL-luc, and luciferase activity was determined as outlined in the section 'Materials and methods'. The results are expressed as meansGS.E.M. for at least three replicate determinations for each treatment group and significantly (P!0 . 05) enhanced activity after transfections with ERa (*) and decreased activity after transfection with siMDM2 (**) are indicated. Figure 7 MDM2 regulates ERa-and E 2 -dependent genes and responses in breast cancer cells. The effects of siMDM2 on E2F1 protein levels in ZR-75 (A) and T47D (B) cells. Cells were transfected with siCT (nonspecific) or siMDM2, treated with 10 nM E 2 for 0, 6, or 12 h, and whole cell lysates were analyzed for E2F1 and b-actin (loading control) by western blots as described in the section 'Materials and methods'. The effects of siMDM2 on E2F1 and pS2 mRNA levels in ZR-75 (C) and T47D (D) cells. Cells were transfected with siCT (nonspecific) or siMDM2, treated with DMSO or 10 nM E 2 for the indicated times, and mRNA levels were determined by real-time PCR as described in the section 'Materials and methods'. The results are expressed as meansGS.E.M. for three replicate determinations and significant (P!0 . 05) induction by E 2 (*) and inhibition by siMDM2 (**) are indicated. (E) The effects of Nutlin. T47D or ZR-75 cells were treated with DMSO or 10 nM E 2 in the presence or absence of 5 mM Nutlin and analyzed for E2F1 and b-actin (loading control) by western blots. (F) siMDM2 inhibits growth and hormone-induced cell proliferation. MCF-7 or ZR-75 cells were transfected with siCT or siMDM2, treated with DMSO or 10 nM E 2 , and cells were counted at various time points as described in the section 'Materials and methods'. The results are expressed as meansGS.E.M. for three replicate determinations and significant induction by E 2 (compared to DMSO) (*) and inhibition by siMDM2 (**) are indicated.
For example, b-catenin enhanced interactions between LEF1 (GAL4-LEF1) and GRIP1 (VP-GRIP), and this was primarily due to coactivation and interactions of b-catenin with LEF1 but not with GRIP1. Similarly, this study shows that MDM2 enhanced interactions between ERa and SRCs, and this was primarily associated with coactivation and interactions with ERa since MDM2 and SRCs did not interact. The cooperative coactivation of nuclear receptors by coactivators and other nuclear factors is highly variable. For example, CARM1 and p300 enhanced GRIP1-dependent coactivation of ERa and the former proteins interact with GRIP1 but not with ERa (Chen et al. 2000) . In contrast, the model for coactivation of ERa and ERa/SP1 by SRCs and MDM2 primarily involves MDM2 interactions with ERa and not with SRCs.
Current studies are investigating the role of MDM2 in regulating expression of E 2 -responsive genes with ERE and GC-rich promoters and determining their cyclical interactions with gene promoters and other coactivators using ChIP assays. Our results clearly demonstrate that MDM2 enhances ER-dependent transactivation and cell proliferation (Fig. 7) , and in transactivation assays, the loss of hormone responsiveness in cells transfected with siMDM2 was p53 independent (data not shown). Cotransfection of cells with siMDM2 alone or siMDM2 plus sip53 gave similar results, whereas knockdown of p53 alone (sip53) slightly enhanced hormone-induced transactivation, and this was consistent with a recent study (Akaogi et al. 2009 ) and a report showing that p53 decreases hormone-induced transactivation (Liu et al. 1999) . In breast cancer, the potential prognostic significance of MDM2 or an MDM2 promoter polymorphism (SNP309) that enhances MDM2 expression has been inconsistent (Wilkening et al. 2007 ). However, examination of the publically available Nederlands Kanker Instituut (NKI) gene expression data from ER-positive breast cancer patients (van de Vijver et al. 2002) shows that low-MDM2 levels predict a higher overall and relapse-free survival compared with patients with high-MDM2 levels (data not shown) and this observation is consistent with the results of this study showing the critical role of MDM2 in hormone-induced gene expression and growth of ER-positive breast cancer cells, suggesting that MDM2 inhibitors may be efficacious for treatment of ER-positive breast cancer patients. However, it should also be noted that the loss of MDM2 and the decreased MCF-7 and ZR-75 cell proliferation (Fig. 7F ) may also be due to the parallel activation of p53 after MDM2 knockdown.
Declaration of interest
